477864-09-8

Basic information

• Product Name: 1-BOC-4-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE
• Synonyms: 1-BOC-4-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE;TERT-BUTYL 4-[3-(TRIFLUOROMETHYL)ANILINO]TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE
• CAS NO: 477864-09-8
• Molecular Formula: C₁₇H₂₃F₃N₂O₂
• Molecular Weight: 344.37
• Mol File: 477864-09-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE(477864-09-8)
• EPA Substance Registry System: 1-BOC-4-(3-TRIFLUOROMETHYL-PHENYLAMINO)-PIPERIDINE(477864-09-8)

Safety Data

• Hazardous Substances Data: 477864-09-8(Hazardous Substances Data)

Usage

Chemical class

Piperidine derivatives

Explanation

1-BOC-4-(3-trifluoromethyl-phenylamamino)-piperidine belongs to a class of chemical compounds that have a piperidine ring in their structure.

Explanation

This compound is commonly used as a starting material or building block in the synthesis of various pharmaceuticals and other molecules with biological activity.

Explanation

The BOC group is attached to the nitrogen atom of the piperidine ring, providing stability and allowing for further chemical manipulation of the molecule.

Explanation

The presence of this group on the piperidine ring makes the compound an important intermediate in the synthesis of diverse pharmacologically relevant compounds.

Explanation

Due to its unique structure and properties, 1-BOC-4-(3-trifluoromethyl-phenylamamino)-piperidine is widely used in the fields of medicinal chemistry and drug discovery research for the development of new therapeutic agents.

Use in organic synthesis

Building block for pharmaceuticals and biologically active molecules

BOC protecting group

tert-butoxycarbonyl

Trifluoromethyl-phenylamino group

Presence on the piperidine ring

Application in research

Medicinal chemistry and drug discovery

Upstream product

• 401-81-0 m-trifluoromethylphenyl iodide 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 98-16-8 3-trifluoromethylaniline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1247029-73-7 N-[3-(trifluoromethyl)phenyl]piperidin-4-amine, hydrochloride salt 
• 782446-06-4 4-((3-trifluoromethyl-phenyl)-amino)-piperidine 

Relevant articles and documents

The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, th

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators

The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.